Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: PGIC; PGIC.PR.A) (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders...
-
TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: MPY) Mulvihill Premium Yield Fund (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net assets...
-
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hitek...
-
RADNOR, Pa., March 28, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) a nationally recognized securities litigation law firm, is investigating potential violations of...
-
TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net...
-
RADNOR, Pa., March 28, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) a nationally recognized securities litigation law firm, is investigating potential violations of...
-
Case alleges defendants failed to disclose Super Micro sales of servers were to companies based in China, in violation of U.S. export control laws.
-
AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE,...
-
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...
-
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...